Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse for at evaluere effektiviteten, sikkerheden og tolerabiliteten af ​​IMU-838 hos patienter med recidiverende multipel sklerose (ENSURE-1)

28. september 2026 opdateret af: Immunic AG

Et multicenter, randomiseret, dobbeltblindet fase 3-studie for at evaluere effektiviteten, sikkerheden og tolerabiliteten af ​​IMU-838 versus placebo hos voksne med recidiverende multipel sklerose (ENSURE-1)

Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU-838 in adult patients with RMS. The study will consist of the following periods:

Screening Period: Approximately 28 days Main Treatment Period: Up to 72 weeks (approximately 15 months) Open Label Extension Period: Up to approximately 8 years

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1121

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Tirana, Albanien, 1005
        • Klinika Mjekesore Nuova, Neurology Clinic
      • Tirana, Albanien
        • Hygeia Hospital Tirana
      • Algiers, Algeriet, 16000
        • University Hospital Center Mustapha Pacha, Algiers
      • Annaba, Algeriet, 23000
        • University Hospital Center Ibn Sina, Annaba
      • Oran, Algeriet, 31000
        • University Hospital Center of Oran
      • Blagoevgrad, Bulgarien, 2700
        • MHAT Puls AD
      • Burgas, Bulgarien, 8000
        • MHAT "Heart and Brain", EAD
      • Pleven, Bulgarien, 5800
        • MC Exacta Medica OOD
      • Pleven, Bulgarien, 5800
        • MHAT Avis Medica
      • Pleven, Bulgarien, 5800
        • UMHAT Dr.Georgi Stranski EAD
      • Pleven, Bulgarien
        • Heart and Brain University Hospital
      • Pleven, Bulgarien
        • MC Vita 1
      • Plovdiv, Bulgarien, 4002
        • UMHAT Sveti Georgi
      • Plovdiv, Bulgarien, 4001
        • UMHAT "Kaspela"EOOD
      • Plovdiv, Bulgarien, 4002
        • UMHAT "Pulmed" Ltd
      • Rousse, Bulgarien
        • UMHAT "Medica Ruse"
      • Sofia, Bulgarien, 1431
        • UMHAT "Alexandrovska"
      • Sofia, Bulgarien, 1431
        • UMHAT "Alexandrovska" EAD
      • Sofia, Bulgarien
        • Military Medical Academy
      • Sofia, Bulgarien, 1606
        • Military Medical Academy MHAT
      • Sofia, Bulgarien, 1000
        • CCB Medical Institute Ministry of Interior
      • Sofia, Bulgarien, 1000
        • Diagnostic and Consultative Center Neoclinic
      • Sofia, Bulgarien, 1000
        • UMHAT "Sveti Ivan Rilski" EAD
      • Sofia, Bulgarien, 1113
        • MHATNP "Sveti Naum", EAD
      • Sofia, Bulgarien, 1113
        • MHATNPsy Sveti Naum EAD
      • Sofia, Bulgarien, 1618
        • MHAT "Sveta Sofia" EOOD
      • Sofia, Bulgarien
        • UMHAT"Tsaritsa Yoanna -ISUL
      • Sofia, Bulgarien
        • UMHATEM N.Pirogov
      • Varna, Bulgarien
        • UMHAT "Sveta Marina" EAD, First Clinic of Neurological Diseases
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85004
        • Xenoscience, Inc., 21st Century Neurology
    • California
      • West Hollywood, California, Forenede Stater, 90048
        • Regina Berkovich MD, PhD Inc. MS Neurology
    • Florida
      • Bradenton, Florida, Forenede Stater, 34205
        • Bradenton Research Center
      • Naples, Florida, Forenede Stater, 34105
        • Collier Neurologic Specialists
      • Ormond Beach, Florida, Forenede Stater, 32174
        • Neurology Associates of Ormond Beach
    • Illinois
      • Northbrook, Illinois, Forenede Stater, 60062
        • Consultants in Neurology, Ltd
      • Tbilisi, Georgien
        • LTD Aversi Clinic
      • Tbilisi, Georgien, 0141
        • 1st Uni Clinic of Tbilisi LEPL
      • Tbilisi, Georgien
        • Eristavi Experimental Center
      • Tbilisi, Georgien
        • J.S.C. Curatio Clinic
      • Tbilisi, Georgien
        • Khechinashvili University Hospital
      • Tbilisi, Georgien
        • LTD New Hospitals
      • Tbilisi, Georgien
        • MediClub Georgia LLC
      • Tbilisi, Georgien
        • Sarajishvili Neurology Institute
      • Tbilisi, Georgien
        • JSC "Jerarsi"
      • Tbilisi, Georgien
        • Pineo Medical Ecosystem LTD
      • Bangalore, Indien, 560092
        • Medstar Speciality Hospital
      • Mangalore, Indien, 575002
        • Mallikatte, Kadri
      • Nagpur, Indien
        • Jasleen Hospital
      • New Delhi, Indien, 110060
        • Sir Ganga Ram Hospital
      • Pune, Indien, 411001
        • Ruby Hospital
      • Shimla, Indien, 171006
        • Atal Institute of Medical Super Specialities (AIMSS)
      • Varanasi, Indien, 221005
        • Institute of Medical Sciences Banaras Hindu University,IMS BHU Varanasi
      • Amman, Jordan, 11942
        • Jordan University Hospital
      • Amman, Jordan, 11196
        • Istiklal Hospital
      • Amman, Jordan
        • TSH Advanced Clinical Center
      • Irbid, Jordan
        • Irbid Speciality Hospital
      • Beirut, Libanon
        • Hotel Dieu de France Hospital
      • Hamra, Libanon, 1107-2020
        • AUB Medical Center
      • Kaunas, Litauen, 50161
        • Lietuvos Sveikatos Mokslu Universitetas - Kauno Klinikos
      • Culiacán, Mexico, 80020
        • Neurociencias Estudios Clínicos S.C
      • Guadalajara, Mexico, 44670
        • Instituto Jalisciense de Metabolismo, SC
      • Mexico City, Mexico, 14050
        • Unidad de Investigación en Salud de Chihuahua S.C.
      • Mexico City, Mexico
        • Clinstile SA de CV
      • Mexico City, Mexico, 03310
        • Grupo medico camino SC
      • Mexico City, Mexico, 06700
        • Consultorio Médico Expert Brain Clinic
      • Morelia, Mexico, 58000
        • Centro de Morelia
      • Veracruz, Mexico, 91900
        • Sociedad de Metabolismo y Corazon, S.C.
      • Veracruz, Mexico, 91900
        • Faicic de RL de CV
      • Chisinau, Moldova
        • Instititute of Emergency Medicine
      • Chisinau, Moldova
        • Medico-Sanitary Public Institution, Institute of Neurology and Neurosurgery "Diomid Gherman"
      • Chisinau, Moldova
        • The Diomid Gherman Institute of Neurology and Neurosurgery
      • Nikšić, Montenegro
        • General Hospital Niksic
      • Podgorica, Montenegro
        • Clinical Center of Montenegro
      • Skopje, Nordmakedonien
        • Hospital "8 mi Septemvri"
      • Skopje, Nordmakedonien
        • University Clinic of Neurology
      • Lublin, Polen, 20-064
        • NZOZ Neuromed M. i M. Nastaj Sp. P.
      • Barnaul, Rusland, 656045
        • City Hospital #5, Barnaul
      • Barnaul, Rusland, 656906
        • Profimed LLC
      • Bryansk, Rusland, 241033
        • Bryansk Regional Hospital 1
      • Chelyabinsk, Rusland, 454021
        • Regional Clinical Hospital 3
      • Krasnoyarsk, Rusland, 660037
        • Federal Siberian Scientific and Clinical Centre of Federal Medical and Biological Agency
      • Kursk, Rusland, 305007
        • Kursk Regional Clinical Hospital
      • Nizhny Novgorod, Rusland, 603076
        • Medis LLC
      • Novosibirsk, Rusland, 630004
        • Sibneiromed LLC
      • Novosibirsk, Rusland, 630007
        • SDMCH SDMC of FMBA of Russia
      • Perm, Rusland, 614045
        • Perm State Medical University n.a. Acad. E. A. Vagner
      • Samara, Rusland, 443095
        • Samara regional clinical hospital n. a. V. L. Seredavin
      • Yekaterinburg, Rusland, 620102
        • Sverdlovsk Regional Clinical Hospital #1
      • Münster, Tyskland, 48149
        • University Hospital Muenster, Institute Translational Neurology dept. Neurology
      • Chernihiv, Ukraine, 14029
        • Communal Non-Commercial Enterprise "Chernihiv Regional Hospital",Department of Neurology
      • Chernivtsi, Ukraine, 58023
        • Regional Municipal Non-commercial Enterprise "Chernivtsi Emergency Medical Hospital"
      • Chernivtsi, Ukraine
        • Chernihiv Regional Hospital
      • Ivano-Frankivsk, Ukraine, 76008
        • Regional Clinical Hospital
      • Ivano-Frankivsk, Ukraine, 76493
        • Neuro Global, LLC
      • Khmelnytskyi, Ukraine
        • Khmelnytsky regional hospital of war veterans
      • Kiev, Ukraine
        • Clinical Hospital #15 of the Podilskyi District of the Kyiv City
      • Kyiv, Ukraine, 3037
        • "Medbud"
      • Kyiv, Ukraine, 4212
        • SMART medical center
      • Kyiv, Ukraine
        • Kyiv City Hospital 4
      • Odesa, Ukraine
        • Odesa Regional Clinical Hospital, Department of Neurosurgery
      • Poltava, Ukraine
        • Medical and diagnostic center of a LLC "Medcontinent", neurology and rehabilitation center
      • Ternopil, Ukraine, 46027
        • Ternopil Psycho-Neuro Hospital
      • Uzhhorod, Ukraine
        • Regional Clinical Center for Neurosurgery and Neurology

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 55 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female patient (age ≥18 to ≤55 years).

  • Patients with an established diagnosis of MS according to 2017 McDonald Criteria.

  • Patients with RMS comprising of relapsing remitting MS (RRMS) and active secondary progressive MS, both defined according to Lublin criteria 1996 and 2014.

  • Active disease as defined by Lublin 2014 evidenced prior to Screening by:

    1. At least 2 relapses in the last 24 months before randomization, or
    2. At least 1 relapse in the last 12 months before randomization, or
    3. A positive Gd+ MRI scan (brain and/or spine) in the last 12 months prior to randomization.
  • Willingness and ability to comply with the protocol.

  • Written informed consent given prior to any study-related procedure.

Exclusion Criteria:

  • Patients with non-active secondary progressive MS and primary progressive MS.
  • Any disease other than MS that may better explain the signs and symptoms, including history of complete transverse myelitis.
  • Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-IgG-associated encephalomyelitis
  • Any active and uncontrolled coexisting autoimmune disease, other than MS (except for type 1 diabetes mellitus and inflammatory bowel disease)
  • Use of experimental/investigational drug (with the exception ofCOVID-19 vaccines approved by emergency use authorization) and/or participation in drug clinical studies within 6 months prior to Screening
  • Previous or current use of MS treatments lifelong, or within a pre-specified time period.
  • Use of the pre-specified concomitant medications.
  • Clinically significantly abnormal and pre-specified lab values.
  • History of chronic systemic infections within 6 months before the date of informed consent.
  • Diagnosis or suspected liver function impairment, which may cause fluctuating liver function tests during this study.
  • Known history of nephrolithiasis or underlying condition with a strong association of nephrolithiasis.
  • History or clinical diagnosis of gout.
  • History or presence of any major medical or psychiatric illness
  • Substantial medical condition that could create undue risk to the patient, could affect adherence with the study protocol or could undesirably affect study outcomes

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: IMU-838

IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH.

Formulation:

Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning.

Patients are randomized to IMU-838 or placebo in ratio 1:1

Andre navne:
  • vidofludimus calcium
Placebo komparator: Placebo

Matching placebo, as described for the test product, identical number of tablets as given for IMU-838.

Patients are randomized to IMU-838 or placebo in ratio 1:1

Andre navne:
  • Placebo matchende vidofludimus calcium

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate efficacy of IMU-838 versus placebo regarding time to first relapse
Tidsramme: 72 weeks

Survival analysis of time to first relapse, occurred after the start of study treatment administration and before the end of the double-blind period, censored at a maximum of 72 weeks.

72 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Effect of IMU-838 versus placebo on volume of new T2 lesions
Tidsramme: 72 weeks

To evaluate the effect of IMU-838 versus placebo on volume of new T2 lesions. Mean difference between IMU-838- and placebo in changes of the volume of new MRI T2 lesions over 24-weeks of treatment in the double-blind period.

72 weeks
Effect of IMU-838 versus placebo on disability progression
Tidsramme: 72 weeks

To evaluate the effect of IMU-838 versus placebo on disability progression. Survival analysis of time to 12-week confirmed disability progression, as measured on Expanded Disability Status Scale during the double-blind period, censored at maximum 72-weeks.

72 weeks
Effect of IMU-838 versus placebo on cognitive performance
Tidsramme: 72 weeks

To evaluate the effect of IMU-838 versus placebo on cognitive performance. Survival analysis of time to confirmed clinically relevant changes on Symbol Digit Modalities Test during the double-blind period, censored at maximum 72-weeks.

72 weeks
Effect of IMU-838 versus placebo on whole brain atrophy
Tidsramme: 72 weeks

To evaluate the effect of IMU-838 versus placebo on whole brain atrophy. Difference in the mean of the percentage change on the whole brain volume between IMU-838 and placebo during the 72-weeks double-blind period.

72 weeks
Safety of IMU-838 versus placebo
Tidsramme: 72 weeks

To evaluate safety and tolerability of IMU-838 versus placebo by assessing rates of Treatment Emergent Adverse Events, Adverse Events of Special Interest, Serious Adverse Events, changes in levels of pre-specified laboratory parameters, vital signs and ECG parameters and rates and reasons for study discontinuations.

72 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Robert J. Fox, MD, Mellen Center for MS, Neurological Institute, Cleveland Clinic, Ohio

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

18. november 2021

Primær færdiggørelse (Anslået)

1. november 2026

Studieafslutning (Anslået)

1. september 2033

Datoer for studieregistrering

Først indsendt

30. september 2021

Først indsendt, der opfyldte QC-kriterier

19. november 2021

Først opslået (Faktiske)

26. november 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • P3-IMU-838-RMS-01

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .